

Delirium Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/DEE8AAC5675AEN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: DEE8AAC5675AEN

Abstracts

The 7 major delirium markets reached a value of US\$ 187.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 283.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.83% during 2024-2034.

The delirium market has been comprehensively analyzed in IMARC's new report titled "Delirium Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Delirium is a sudden and severe impairment of mental function that causes confused thinking and reduced awareness of surroundings. Some of the common symptoms of the disease are the inability to focus or concentrate, difficulty processing information, impaired memory, and hallucinations or delusions. Patients may also experience fluctuations in their level of consciousness, with periods of hyperactivity followed by lethargy or lethargy followed by hyperactivity. Various other indications of delirium include agitation, anxiety, restlessness, sleep disturbances, altered appetite, etc. The diagnosis of delirium is primarily based on a clinical assessment of the patient's symptoms and cognitive function, as well as an examination of their medical history and medications. The healthcare professional may review the patient's medical history and mental status by testing attention, awareness, and thinking. A physical test and neurological examination that include evaluating the vision, coordination, balance, and reflexes are required for further diagnosis. Additionally, several blood, urine, and brain imaging tests are also performed to rule out any underlying issues among patients.

The rising prevalence of neurological disorders, owing to several associated triggering factors, including genetic defects, congenital abnormalities, nerve injuries, etc., is primarily driving the delirium market. In addition to this, the widespread adoption of medications like antipsychotics and benzodiazepines for managing the symptoms of

delirium, such as agitation, hallucinations, delusions, etc., is further acting as a significant growth-inducing factor. Moreover, the escalating usage of cognitive testing, including the mini-mental state examination (MMSE), as part of the delirium diagnosis to assess baseline cognitive function and detect changes associated with the ailment is also propelling the market growth. Apart from this, several key players are making extensive investments in understanding the underlying mechanisms of delirium, such as changes in brain function and the role of inflammation, for identifying new approaches to prevention and treatment of the disease. This, in turn, is further creating a positive outlook for the market. Additionally, the emerging popularity of standardized assessment tools, including the confusion assessment method (CAM) and the delirium observation screening scale (DOSS), which enable non-psychiatrically trained clinicians to identify and diagnose the ailment accurately and quickly, is expected to drive the delirium market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the delirium market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for delirium and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the delirium market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the delirium market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the delirium market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current delirium marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the delirium market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the delirium market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the delirium market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of delirium across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of delirium by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of delirium by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of delirium by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with delirium across the seven major markets?

What is the size of the delirium patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of delirium?

What will be the growth rate of patients across the seven major markets?

Delirium: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for delirium drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the delirium market?

What are the key regulatory events related to the delirium market?

What is the structure of clinical trial landscape by status related to the delirium market?

What is the structure of clinical trial landscape by phase related to the delirium market?

What is the structure of clinical trial landscape by route of administration related to the delirium market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 DELIRIUM - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 DELIRIUM - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 DELIRIUM - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

7.6.7 Patient Pool/Treated Cases (?2018-2034?)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (?2018-2034?)

7.7.4 Epidemiology by Gender (?2018-2034?)

7.7.5 Epidemiology by Type (?2018-2034?)

7.7.6 Diagnosed Cases (?2018-2034?)

7.7.7 Patient Pool/Treated Cases (?2018-2034?)

7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.8.3 Epidemiology by Age (?2018-2034?)

7.8.4 Epidemiology by Gender (?2018-2034?)

7.8.5 Epidemiology by Type (?2018-2034?)

7.8.6 Diagnosed Cases (?2018-2034?)

7.8.7 Patient Pool/Treated Cases (?2018-2034?)

7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

7.9.3 Epidemiology by Age (?2018-2034?)

7.9.4 Epidemiology by Gender (?2018-2034?)

7.9.5 Epidemiology by Type (?2018-2034?)

7.9.6 Diagnosed Cases (?2018-2034?)

7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 DELIRIUM - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment

8.2 Treatment Algorithm

9 DELIRIUM - UNMET NEEDS

10 DELIRIUM - KEY ENDPOINTS OF TREATMENT

11 DELIRIUM - MARKETED PRODUCTS

11.1 List of Delirium Marketed Drugs Across the Top 7 Markets

- 11.1.1 Drug Name – Company Name
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 DELIRIUM - PIPELINE DRUGS

12.1 List of Delirium Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Suvorexant - Merck & Co
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
- 12.1.2 CN 105 - CereNova
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. DELIRIUM - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. DELIRIUM – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 DELIRIUM - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Delirium - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Delirium - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Delirium - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Delirium - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Delirium - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Delirium - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Delirium - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Delirium - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Delirium - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Delirium - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Delirium - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Delirium - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Delirium - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Delirium - Access and Reimbursement Overview

15.7 Market Scenario - Italy

15.7.1 Delirium - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Delirium - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Delirium - Access and Reimbursement Overview

15.8 Market Scenario - Spain

15.8.1 Delirium - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Delirium - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Delirium - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Delirium - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Delirium - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Delirium - Access and Reimbursement Overview

16 DELIRIUM - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 DELIRIUM MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 DELIRIUM MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Delirium Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/DEE8AAC5675AEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DEE8AAC5675AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

